Long-term effect of bariatric surgery versus conventional therapy in obese Korean patients: a multicenter retrospective cohort study

Ji Yeon Park¹, Yoonseok Heo²,³, Yong Jin Kim⁴*, Joong-Min Park⁵, Seong-Min Kim⁶, Do-Joong Park⁷, Sang Kuon Lee⁸, Sang-Moon Han⁹*, Kyung-Won Shim¹⁰, Yeon Ji Lee¹¹, Ja Youn Lee¹², Jin-Won Kwon¹³-¹⁲

¹Department of Surgery, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, Korea
²Department of Surgery, Inha University School of Medicine, Incheon, Korea
³National Evidence-based Healthcare Collaborating Agency, Seoul, Korea
⁴Department of Surgery, Soochunhyang University Seoul Hospital, Seoul, Korea
⁵Department of Surgery, Chung-Ang University College of Medicine, Seoul, Korea
⁶Department of Surgery, Gachon University College of Medicine, Incheon, Korea
⁷Department of Surgery, Soonchunhyang University Seoul Hospital, Seoul, Korea
⁸Department of Surgery, Chung-Ang University College of Medicine, Seoul, Korea
⁹Department of Surgery, Chung-Ang University College of Medicine, Incheon, Korea
¹⁰Department of Family Medicine, Ewha Women’s University School of Medicine, Seoul, Korea
¹¹Department of Family Medicine, Inha University School of Medicine, Incheon, Korea
¹²College of Pharmacy, Kyungpook National University, Daegu, Korea

Purpose: Long-term results following bariatric surgery compared to conventional treatments has never been reported in morbidly obese Korean patients. This study aimed to evaluate the long-term efficacy of bariatric surgery in morbidly obese Korean patients compared to conventional medical treatments.

Methods: In this multicenter retrospective cohort study, we reviewed 137 obese subjects between January 2008 and February 2011 with a body mass index (BMI) > 30 kg/m² who had more than 5 years of follow-up clinical data after bariatric surgery (surgery group, n = 49) or conventional treatment (conventional treatment group, n = 88). Anthropometric data and the status of comorbidities were compared between the 2 groups.

Results: The median follow-up period was 72.1 months (range 19.3–109.7 months). At the last follow-up, the surgery group showed a greater amount of total weight loss than the conventional treatment group (24.9% vs. 2.8%, P < 0.001). The prevalence of diabetes and hypertension significantly decreased in the surgery group, while the conventional treatment group showed a marked increase in these comorbidities. In the surgery group, Roux-en-Y gastric bypass and sleeve gastrectomy achieved comparable long-term weight loss (26.5% vs. 22.4%, respectively; P = 0.087).

Conclusion: In the long-term, bariatric surgery achieved and maintained significantly greater weight reduction, as well as a decrease in obesity-related comorbidities, than did conventional medical therapy in morbidly obese Korean patients.

Key Words: Morbid obesity, Bariatric surgery, Gastric bypass, Gastrectomy
INTRODUCTION

Obesity is a growing health problem for most countries around the world and Korea is no exception [1]. According to a nationwide survey, the obese population (defined in Korea as a body mass index [BMI] of over 25 kg/m²), has gradually increased over the last decade from 28.7 % in 2006 to 32.4% in 2015. The morbidly obese population, with a BMI of over 30 kg/m², has increased even more rapidly reaching 4.8% of the total population in 2015 (>800,000 people), with the trend being more prominent in the younger generation [2,3]. Morbid obesity is associated with various comorbidities including: diabetes, dyslipidemia, cardiovascular diseases, fatty liver disease, and obstructive sleep apnea, etc., consequently shortening peoples’ life spans. Medical expenditures associated with obesity were reported to be staggering and increased sharply with the growing incidence of obesity. Despite persistent efforts to control this obesity pandemic, none of the conservative measures, including medication, could successfully achieve long-lasting weight control.

Bariatric surgery is identified as an effective treatment for morbid obesity and leads to sustained weight loss, improvement of many obesity-related comorbidities and the quality of life and prolongs survival. The introduction of laparoscopic surgical techniques in the 1990s has accelerated advancements in bariatric and metabolic fields. This technology has significantly improved technical safety compared to the open surgical era and the number of procedures has exponentially increased 15 fold over the last two decades reaching 634,897 worldwide in 2016 [4,5]. Currently, bariatric surgery is one of the most commonly performed surgical procedures in the field of general surgery in the United States [6]. However, the number of procedures performed in Korea is still limited and the long-term results following bariatric surgery when compared with conventional treatments have never been reported in morbidly obese Korean patients.

This study aimed to evaluate the long-term efficacy of bariatric surgery in morbidly obese Korean patients compared with conventional medical treatments, using anthropometric and obesity-related comorbidity changes over a follow-up duration of more than 5 years.

METHODS

Eligible patients

Eligible patients were described in a previous 2012 retrospective study which investigated the short-term efficacy of bariatric surgery and included 261 surgical patients and 224 nonsurgical patients [7]. Briefly, the surgery group included all obese patients (BMI > 30 kg/m²) who underwent consecutive bariatric surgeries at the surgical departments of 7 tertiary hospitals in Korea between January 2008 and February 2011. The conventional treatment group included patients who were managed with conventional therapies, which means intensive lifestyle modification accompanied by anorectic agents. Intensive lifestyle modification consisted of personalized nutritional education and physical training as well as the lifestyle coaching by obesity specialists at the departments of family medicine, which involved family medicine doctor, dietician and exercise practitioner. The relevant data of these patients were retrospectively collected via medical chart reviews.

The same cohort was used in the present study to evaluate the long-term outcomes (5–7 years) following bariatric surgery versus conservative treatment in patients with a BMI > 30 kg/m². Only 137 out of the eligible 485 patients in the previous study possessed sufficient follow-up clinical information for long-term result analyses. The cutoff date for the data collection was May 30th, 2017 in the present study. Approval for this review of hospital records was obtained from the Institutional Review Board of Inha University Hospital (IRB No. 2016-06-008-011), and the need for patient informed consent was waived.

Data collection

Baseline demographics and clinical characteristics including anthropometric data and past medical histories were collected a few days before each bariatric procedure in the surgery group, or at their first visit to initiate a weight management program in the conventional treatment group. Patients received a 3-month interval follow-up for 2 years, with longer intervals thereafter. Subsequent clinical data at each follow-up visit were retrospectively collected via chart reviews. The degree of weight loss was expressed as the percentage of total weight loss (%TWL), which was calculated by dividing weight changes by the initial weight.

Definition of obesity-related comorbidities

The following definitions were used to define the obesity-related comorbidities. Diabetes was defined as the use of antidiabetic medications, fasting blood glucose ≥ 126 mg/dL, or hemoglobin A₁c level ≥ 6.5%. Hypertension was defined as the use of antihypertensive medications, systolic blood pressure ≥ 140 mmHg, or diastolic blood pressure ≥ 90 mmHg. Dyslipidemia was defined as the used lipid-lowering agents, total cholesterol ≥ 240 mg/dL, triglycerides ≥ 200 mg/dL, or low-density lipoprotein cholesterol ≥ 160 mg/dL. The prevalence of the disease at baseline and at the final follow-up was calculated based on these definitions and compared between the groups.

Statistical analyses

Statistical analyses were performed using IBM SPSS ver. 18.0
Eighty-eight patients in the conventional group and 49 patients in the surgery group were included in the present study. In the surgery group, the primary bariatric procedure was laparoscopic sleeve gastrectomy (SG, n = 19) or Roux-en-Y gastric bypass (RYGB, n = 30). The baseline characteristics of the 137 patients are shown in Table 1. The surgery group had significantly more females (77.6% vs. 58.0%, P = 0.021) and was also significantly younger compared to the nonsurgical group (38.1 years vs. 41.6 years, P = 0.021). At baseline, the surgery group had a higher BMI than those who received conservative treatments (39.0 ± 7.0 kg/m² vs. 33.6 ± 3.1 kg/m², P < 0.001).

The median follow-up period for all patients was 72.1 months (range 19.3–109.7 months) as shown in Table 2. At the last follow-up, patients in the surgery group demonstrated weight loss of 27.1 ± 14.6 kg which was significantly greater than the 2.7 ± 7.3 kg weight loss in the conventional group (P < 0.001). The results correspond to a 24.9% versus 2.8% reduction of the initial total body weight in each group, which was markedly superior in the surgery group (P < 0.001). A closer look at the data revealed that 31 out of 88 patients (35.2%) in the conventional group showed paradoxical weight gain at the last follow-up in comparison with the baseline. In spite of conservative weight management efforts they showed, on average, a 4.2-kg body weight increase during the follow-up period. Patient weight increase after surgical treatment did not occur although the amount of weight loss varied among patients. Chronological changes of body weight showed that a patient’s maximum weight loss occurred between 12 and 18 months after initiation of the treatment for both groups (Fig. 1). Patients in the conventional treatment group achieved a maximum weight loss of 8.6 kg (8.7% in %TWL) 12 months following the initiation of weight management and then showed slow but steady regain of body weight thereafter. They ultimately regained more than half of their total weight lost despite constant efforts to control body weight over the following years. Meanwhile, patients in the surgery group reached their nadir weight at 12–18 months after surgery with weight loss up to 32.3 kg (27.2% in %TWL) and maintained their reduced body weight up to 3 to 5 years without significant weight regain.

The prevalence of obesity-related comorbidities is shown in Table 3. At baseline, type 2 diabetes was more prevalent in the surgery group (51.0%) than in the conventional treatment group (13.6%, P < 0.001). However, the prevalence of diabetes reversed at the last follow-up, which showed an increase in the conventional treatment group compared to the marked decrease in the surgery group. Similarly, the prevalence of hypertension markedly decreased from 65.3% to 24.5% following the surgery, while it increased from 44.3% to 53.4% for those receiving conventional therapy. The prevalence of dyslipidemia decreased in both groups, but the surgery group demonstrated a sharper drop than the conventional treatment group.

The surgery group was comprised of 30 RYGB patients and 19 SG patients. The baseline BMI was significantly higher in SG patients (42.0 ± 7.9 kg/m²) than in RYGB patients (37.1 ± 5.8 kg/m², P = 0.011) (Table 4). At the last follow-up, patients lost 26.5% total body weight following RYGB and 22.4% following SG and were maintained.)

### Table 1. Baseline patient characteristics

| Characteristic         | Conventional therapy group (n = 88) | Surgery group (n = 49) | P-value |
|------------------------|------------------------------------|------------------------|---------|
| Age (yr)               | 41.6 ± 12.7                        | 38.1 ± 11.7            | 0.113   |
| Sex                    |                                     |                        |         |
| Male                   | 37 (42.0)                          | 11 (22.4)              | 0.021   |
| Female                 | 51 (58.0)                          | 38 (77.6)              |         |
| Body weight (kg)       | 90.7 ± 14.2                        | 106.4 ± 25.2           | <0.001  |
| Body mass index (kg/m²)| 33.6 ± 3.1                         | 39.0 ± 7.0             | <0.001  |
| 30–34.9                | 64 (72.7)                          | 17 (34.7)              |         |
| 35–39.9                | 21 (23.9)                          | 16 (32.7)              |         |
| ≥40                    | 3 (3.4)                            | 16 (32.7)              |         |
| Smoking<sup>a</sup>    | 12 (18.8)%                         | 6 (14.3)%              | 0.373   |
| Alcohol consumption    | 31 (49.2)%                         | 10 (20.8)%             | 0.002   |
| Unmarried              | 13 (24.5)%                         | 19 (45.2)%             | 0.034   |

Values are presented as mean ± standard deviation or number (%).<sup>a</sup>Current smoker + past smoker. <sup>b</sup>The percentage among patients with available data.

### Table 2. Anthropometric outcomes at the last follow-up

| Variable                | Conventional therapy group (n = 88) | Surgery group (n = 49) | P-value |
|-------------------------|------------------------------------|------------------------|---------|
| Follow-up (mo)          | 73.7 (53.4–87.2)                   | 71.0 (50.1–75.2)       | 0.056   |
| ΔBody weight (kg)<sup>a</sup> | 2.7 ± 7.3                        | 27.1 ± 14.6            | <0.001  |
| ΔBMI (kg/m²)<sup>a</sup> | 1.0 ± 2.8                         | 9.9 ± 5.2              | <0.001  |
| %TWL (%)<sup>b</sup>    | 2.8 ± 8.0                         | 24.9 ± 9.6             | <0.001  |
| Weight change status    |                                     |                        |         |
| Weight loss             | 57 (64.8)                         | 49 (100)               | <0.001  |
| Weight gain             | 31 (35.2)                         | 0 (0)                  |         |

Values are presented as median (interquartile range), mean ± standard deviation, or number (%). BMI, body mass index; %TWL, percent of total weight loss. <sup>a</sup>Positive value indicates reduced amount. <sup>b</sup>%TWL = Δ Body weight/baseline body weight × 100.
Annals of Surgical Treatment and Research 2019;96(6):283-289

SG; the difference was marginally significant (P = 0.087). The chronological changes of body weight and %TWL demonstrated a similar pattern of weight loss without a statistically significant difference between the 2 procedures (Fig. 2).

Eight out of 19 SG patients (42.1%) required revisional surgery during the follow-up period and all of them were converted to RYGB. The specific causes for the conversion were as follows: 3 patients for intractable gastroesophageal reflux, 2 for poorly-controlled diabetes, 2 for insufficient weight loss, and 1 for gastric tube stricture.

DISCUSSION

The present study demonstrated that the efficacy of bariatric surgery was superior to conventional therapy in terms of long-term weight reduction and maintenance. This study was an extension of a previous study which compared the short-term efficacy of bariatric surgery compared to medical therapy in weight and comorbidity management in morbidly obese Koreans. Prolonged follow-up of this identical cohort showed that the patients in the surgical group successfully maintained their weight loss for over 5–7 years compared to those in the conventional treatment group who showed slow weight regain.

**Table 3.** Changes in the incidence of obesity-related comorbidities

|                        | Conventional therapy group (n = 88) | Surgery group (n = 49) | P-value\(^a\) |
|------------------------|-------------------------------------|------------------------|----------------|
| Diabetes               |                                     |                        |                |
| Baseline               | 12 (13.6)                           | 25 (51.0)              | <0.001         |
| Last follow-up         | 22 (25.0)                           | 16 (32.7)              | 0.370          |
| Hypertension           |                                     |                        |                |
| Baseline               | 39 (44.3)                           | 32 (65.3)              | 0.018          |
| Last follow-up         | 47 (53.4)                           | 12 (24.5)              | 0.001          |
| Dyslipidemia           |                                     |                        |                |
| Baseline               | 39 (44.3)                           | 17 (34.7)              | 0.272          |
| Last follow-up         | 37 (42.0)                           | 4 (8.2)                | <0.001         |

Values are presented as number (%).

*P*earson chi-square test.
after the first year of enrollment in the weight management program. To our knowledge, this is the first Korean report which addresses the long-term outcomes in morbidly obese patients undergoing bariatric surgery versus those receiving conventional medical treatments.

Over the last several decades, numerous studies have already clearly demonstrated the short-term superiority of bariatric surgery over conventional weight management therapy which includes the previous Korean multicenter study [7]. However, evidence for long-term surgical efficacy has not been evaluated to a great extent, since a substantial proportion of the patients are usually lost to follow-up within a few years after bariatric surgery. It is difficult to discuss the prolonged benefit of bariatric surgery without referring to the monumental Swedish Obese Subjects study, which is a prospective, interventional, case-controlled study designed to elucidate the long-term effects of bariatric surgery in comparison with medical treatments [8]. Although some of the surgical procedures adopted in that study are now no longer in use, the study is still ongoing and has followed the recruited obese subjects for more than 10–15 years, producing voluminous results [9]. They dealt with a wide range of health issues related to obesity which demonstrated the superiority of surgical intervention over conventional therapies in terms of sustained weight loss and its association with lower mortality, resolution of comorbidities, occurrence of de novo diabetes or other metabolic and malignant diseases, health-related quality of life, and socio-economic aspects [10-14]. Other representative randomized controlled trials comparing surgical versus medical therapy have shown similar results demonstrating significantly greater weight reduction along with better glycemic control in the surgical group [15,16]. These studies uniformly revealed that the surgical patients reached their nadir weight at 1–2 years followed by slight weight regain in subsequent years. Although the efficacy varied depending on the type of procedures used, bariatric surgery achieved 14%–31% of total weight loss after 5 years or more compared to the minimal changes following conventional treatments. This is consistent with weight trajectories shown in the present study among Korean patients with comparable weight loss in the surgery group (24.9%) at the median follow-up of 73.7 months.

Regarding obesity-related comorbidities, our data was insufficient to be able to delineate whether the patients with diabetes, hypertension, or dyslipidemia at baseline experienced remission or relapse over time following each treatment. Instead, only the prevalence of each disease at baseline and

![Fig. 2. Anthropometric chronological changes following Roux-en-Y gastric bypass (RYGB) versus sleeve gastrectomy (SG). Body mass index (BMI, kg/m²) (A) and percent of total weight loss (%TWL) (B). M, month.](image)

**Table 4.** Comparison of the baseline characteristics and surgical outcomes following Roux-en-Y gastric bypass vs. sleeve gastrectomy

| Variable                        | RYGB (n = 30) | SG (n = 19) | P-value |
|---------------------------------|--------------|------------|---------|
| Age (yr)                        | 40.2 ± 12.9  | 34.7 ± 8.8 | 0.234   |
| Sex                             |              |            |         |
| Male                            | 6 (20.0)     | 5 (26.3)   | 0.729   |
| Female                          | 24 (80.0)    | 14 (73.7)  |         |
| Baseline body weight            | 100.7 ± 23.4 | 115.3 ± 25.9| 0.029   |
| Baseline BMI                    | 37.1 ± 5.8   | 42.0 ± 7.9 | 0.011   |
| At last follow-up               |              |            |         |
| Follow-up duration (mo)         | 63.1 ± 19.4  | 66.4 ± 19.4| 0.535   |
| Δ Body weight (kg)              | 27.3 ± 13.1  | 26.7 ± 17.1| 0.545   |
| Δ BMI (kg/m²)                   | 10.0 ± 4.4   | 9.7 ± 6.3  | 0.356   |
| %TWL (%)                        | 26.5 ± 8.9   | 22.4 ± 10.4| 0.087   |
| Revisional surgery              | 1 (3.3)      | 8 (42.1)   | 0.001   |

Values are presented as mean ± standard deviation or number (%).

RYGB, Roux-en-Y gastric bypass; SG, sleeve gastrectomy; BMI, body mass index; %TWL, percent of total weight loss.

P-value: a) Mann-Whitney U-test. b) Fisher exact test.
revealed that the most discouraging drawback of SG was exacerbated by the aforementioned 2 randomized controlled trials consistently reporting higher %TWL trajectories causing confusion in the interpretation. This high attrition rate may also imply the possibility that only patients with good treatment results were selected, while those with poor outcomes were largely lost to follow-up and excluded in the final analysis. As Puzziferri et al. [19], have pointed out in a previous review, this extent of attrition could cause distortion in data interpretation, and consequently make it difficult to draw a concrete conclusion based on the present study. Therefore, in the future, a better-designed prospective study with acceptable retention rates is required to clearly elucidate the long-term effects of bariatric surgery and to facilitate an optimal therapeutic decision for Korean patients with morbid obesity.

In conclusion, over the long-term, bariatric surgery achieved and maintained significantly greater weight reduction, as well as a decrease in obesity-related comorbidities, than did conventional medical therapies in morbidly obese Korean patients.

**CONFLICTS OF INTEREST**

No potential conflict of interest relevant to this article was reported.

**ACKNOWLEDGEMENTS**

This work was supported by grants from the Korean Health Technology R&D Project (HC15C1322), Ministry of Health & Welfare, Republic of Korea (for YH).
REFERENCES

1. World Health Organization. Obesity and overweight fact sheets [Internet]. Geneva (Switzerland): World Health Organization; c2019 [2018 Oct 10]. Available from: http://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.

2. National Health Insurance Service. National Health Information Database [Internet]. Wonju (Korea): National Health Insurance Service; c2014 [2018 Oct 10]. Available from: https://nhiss.nhis.or.kr/bd/ay/bdaya001iv.do.

3. Shin HY, Kang HT. Recent trends in the prevalence of underweight, overweight, and obesity in Korean adults: The Korean National Health and Nutrition Examination Survey from 1998 to 2014. J Epidemiol 2017;27:413-9.

4. Wittgrove AC, Clark GW, Tremblay LJ. Laparoscopic gastric bypass. roux-en-Y: preliminary report. Obes Surg 1994;4:353-7.

5. Scopinaro N. The IFSO and obesity surgery throughout the world. International Federation for the Surgery of Obesity. Obes Surg 1998;8:3-8.

6. Pierce J, Galante J, Scherer LA, Chang EJ, Wisner D, Ali M. PL-202: bariatric surgery versus conventional therapy in obese Korea patients: a multicenter retrospective cohort study. J Korean Surg Soc 2012;83:335-42.

7. Heo YS, Park M, Kim YJ, Kim SM, Park DJ, Lee SK, et al. Bariatric surgery versus conventional therapy in obese Korean patients: a multicenter retrospective cohort study. J Korean Surg Soc 2012;83:335-42.

8. Sjostrom L, Larsson B, Backman L, Bengtsson C, Bouchard C, Dahlgren S, et al. Swedish obese subjects (SOS). Recruitment for an intervention study and a selected description of the obese state. Int J Obes Relat Metab Disord 1992;16:465-79.

9. Sjostrom L. Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J Intern Med 2013;273:219-34.

10. Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, Wedel H, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007;357:741-52.

11. Sjostrom L, Gummesson A, Sjostrom CD, Narbro K, Peltonen M, Wedel H, et al. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol 2009;10:653-62.

12. Sjostrom L, Peltonen M, Jacobsson P, Ahlin S, Andersson-Assarsson J, Anveden A, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 2014;311:2297-304.

13. Sjostrom L, Peltonen M, Jacobson P, Ahlin S, Andersson-Assarsson J, Anveden A, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 2014;311:2297-304.

14. Carlsson LM, Peltonen M, Ahlin S, Anveden A, Bouchard C, Carlsson B, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med 2012;367:695-704.

15. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Nanni G, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5-year follow-up of an open-label, single-centre, randomised controlled trial. Lancet 2015;386:964-73.

16. Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Aminian A, Brethauer SA, et al. Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes. N Engl J Med 2017;376:641-51.

17. Peterli R, Wolnerhanssen BK, Peters T, Vetter D, Kroll D, Borbely Y, et al. Effect of laparoscopic sleeve gastrectomy vs laparoscopic roux-en-Y gastric bypass on weight loss in patients with morbid obesity: the SM-BOSS randomized clinical trial. JAMA 2018;319:255-65.

18. Salminen P, Helmio M, Ovaska J, Juuti A, Leivonen M, Peromaa-Haavisto P, et al. Effect of laparoscopic sleeve gastrectomy vs laparoscopic roux-en-Y gastric bypass on weight loss at 5 years among patients with morbid obesity: the SLLEEVEPASS randomized clinical trial. JAMA 2018;319:241-54.

19. Puzziferri N, Roshek TB 3rd, Mayo HG, Gallagher R, Belle SH, Livingston EH. Long-term follow-up after bariatric surgery: a systematic review. JAMA 2014;312:934-42.

20. Schooerer A, Kasten K, Celio A, Pories W. Spaniolas K. The effect of close post-operative follow-up on co-morbidity improvement after bariatric surgery. Surg Obes Relat Dis 2017:13:1347-52.

21. Gould JC, Beverstein G, Reinhardt S, Garren MJ. Impact of routine and long-term follow-up on weight loss after laparoscopic gastric bypass. Surg Obes Relat Dis 2007;3:627-30.

22. Compher CW, Hanlon A, Kang Y, Elkin L, Williams NN. Attendance at clinical visits predicts weight loss after gastric bypass surgery. Obes Surg 2012;22:927-34.

23. Aarts MA, Sivapalan N, Nikkad SE, Serodio K, Sockalingam S, Conn LG. Optimizing bariatric surgery multidisciplinary follow-up: a focus on patient-centered care. Obes Surg 2017;27:730-6.